Replies to post #123259 on Biotech Values

[DewDiligence]

MNTA—You ready to chime in yet about the Day-1 [Copaxone mini-trial] comments from Jeffries?

The Jefferies analyst didn’t say anything surprising, IMO. I’ve been saying all along that prevailing on the inequitable conduct argument will be tough (#msg-63619477).